•  

Toronto Innovation Acceleration Partners – TIAP – specializes in  venture building of

early-stage health science technologies emerging from our members.

TIAP was formerly MaRS Innovation

Our Members
TIAP’s portfolio draws from the University of Toronto, seven teaching hospitals and two research institutes. Learn more about our members.
Learn More
Work With Us
Through our member-exclusive funding programs and services, TIAP works with founders to bring their health science technologies to market faster.
Learn More
Recent News

FedDev Ontario Funding Support – Portfolio Investments

On October 9, 2020, the Honourable Mélanie Joly, then Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev …

TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen

TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb
LAB150 was created in 2017 …

Phase 2 clinical trial targeting diabetes

TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.
Why this news is important:

Zucara has achieved the development milestones required to secure the remaining …

Highly Positive Results from PoC Phase 1b trial of ZT-01 – Type 1 Diabetes

Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:

This trial confirms ZT-01’s mechanism of action in restoring …

TIAP shifted my perspective from BlueDot's research to its potential as a global business. They worked with me to incorporate the company, develop a business plan and model suitable for a social enterprise, and hire key talent, while supporting me through BlueDot’s early stages of growth and development.
Kamran Khan, MD, MPH
Founder / BlueDot
TIAP understood the value of my invention and saw its potential when others didn’t (they’re starting to now!). I’m grateful for the investment and mentoring I received through the UTEST program.
James Colliander, PhD
Co-Founder / Crowdmark
The UTEST program and TIAP have been fantastic for TrendMD; we would not be where we are today without them. Both from a strategic and financial perspective, UTEST definitely served as the initial spark that was crucial for getting us off the ground.
Paul Kudlow, MD
Founder / TrendMD
TIAP’s unique ecosystem allows innovators and researchers to keep the high impact of their innovation while enabling it with frameworks for commercialization. Their dedicated expert team allowed us to launch, structure and scale our company both in Canada and in the rest of the world while allowing us to maintain our research and academic mandates.
Hossein Rahnama, PhD
Founder / Flybits
TIAP was a vital partner as we refined our technology, our business model and our go-to-market strategy. Without their support, and the support of UTEST, we would not be in the position we are today.
Craig Boutilier, PhD
Co-Founder / Granata Decision Systems